Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells

Abstract

These results strongly indicate functional roles for CD133 in ROS defense and in evading anticancer therapies in HCC, and suggest that sulfasalazine, administered in combination with conventional chemotherapy, might be an effective strategy against CD133-positive HCC cells.